ClinicalTrials.gg
CompletedNCT00006436Updated Aug 3, 2026Results posted

EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection

A Phase 2 interventional study of Rituximab and Filgrastim in Lymphoma, AIDS-related and Lymphoma, Large B-Cell, Diffuse, sponsored by National Cancer Institute (NCI). Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-03.

Sponsored by National Cancer Institute (NCI) · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
68
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Lymphoma, AIDS-Related with a site in United States — none open to participants now, 1 under way, none of them phase 3. Lymphoma, AIDS-Related · United States.

Started
2001
the only one that year
Phase 2
5 of 12
none open now
Registered
7th of 12
by date
Lead sponsor
5 of 12
National Cancer Institute (NCI)

Among the 12 studies in Lymphoma, AIDS-Related with a site in United States, this one is the only one that started in 2001, is one of 5 in phase 2, and was the 7th registered.

Lymphoma, AIDS-Related

25 studies on the registry are indexed under Lymphoma, AIDS-Related; 2 are open to participants now.

Browse Lymphoma, AIDS-Related studies →

Open to participants now

None of the 12 studies in Lymphoma, AIDS-Related with a site in United States is open now. The open studies under Lymphoma, AIDS-Related, anywhere →

Who these studies take

Of the 2 Lymphoma, AIDS-Related studies recruiting now, 2 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Lymphoma, AIDS-Related with a site in United States as a file.
02

Study summary

Background:

  • Human immunodeficiency virus (HIV)-infected patients have a weakened immune system, and chemotherapy, which is used to treat lymphoma, probably causes further damage to the immune system.
  • Limiting the amount of immune damage due to chemotherapy might decrease the number of infections and the risk of developing cancer in the future in HIV-infected patients with non-Hodgkin's lymphoma.

Objectives:

  • To determine whether reducing the total amount of chemotherapy using a specific combination of drugs called EPOCH-R (etoposide, doxorubicin, vincristine, cyclophosphamide and rituximab) will rid the body of lymphoma quickly while decreasing the risk of infections and future cancers.
  • To determine whether the lymphoma will remain undetectable for at least one year if treatment is stopped one cycle after the patient enters remission.

Eligibility:

-Patients with non-Hodgkin's lymphoma and HIV infection 4 years of age and older who have not been treated previously with rituximab or cytotoxic chemotherapy.

Design:

  • Patients receive EPOCH-R in 3-week treatment cycles for at least three and no more than six cycles.
  • The lymphoma is evaluated using computed tomography (CT) and positron emission tomography (PET) scans at the end of treatment cycles 2 and 3. A bone marrow biopsy is repeated after cycle 2 if a biopsy was initially positive on screening for participation in the study.
  • Anti-HIV therapy is stopped before chemotherapy begins and is restarted when EPOCH-R treatment ends.
  • Patients are monitored for treatment response with blood tests and imaging scans at baseline, when treatment ends, 2 months after treatment ends and then every 3 to 6 months for a total of 24 months following chemotherapy.
Read the detailed description

Background:

This is a study to investigate in a preliminary fashion the feasibility of short course chemotherapy to participants with HIV-associated non-Hodgkin's lymphoma (HIV-NHL).

This study will investigate if the paradigm for treatment can be successfully changed from a standard of 6 cycles to one cycle beyond complete remission with 6 total allowable cycles.

Objective:

To assess with 90 percent probability that at least 50 percent of participants treated with short-course EPOCH-R (etoposide, doxorubicin, vincristine, cyclophosphamide and rituximab) will be progression free at one year.

Eligibility:

Aggressive B-lymphocyte antigen CD20 (CD20) positive Diffuse large B cell lymphoma (DLBCL).

HIV+ serology.

All stages (I-IV) of disease.

Eastern Cooperative Oncology Group (ECOG) Performance status 0-4.

Non-Hodgkin's Lymphoma (NHL) previously untreated with cytotoxic chemotherapy.

Age greater than or equal to 18 years.

May not be pregnant or nursing.

May not have received previous rituximab.

Design:

Participants will be treated every three weeks with a combination of EPOCH and rituximab for one cycle beyond complete remission (CR)/complete response unconfirmed (CRu) by computed tomography (CT) scan of all detectable tumors for a minimum of three and maximum of six cycles. Following cycle 2, CT, positron emission tomography scans (PET), and bone marrow biopsies (if initially positive) will be performed.

At the conclusion of the study, we will estimate whether the number of cycles can be reduced using the paradigm. If the cumulative number of participants to relapse exceeds 25 percent by 6 months, the study will be closed.

Following the completion of chemotherapy, restaging will be performed 2 months following the end of treatment, then every 3 months for one year, every 6 months for one year, then every 12 months until relapse, death, or loss to follow up.

Antiretroviral therapy (ART) will be given concurrently with treatment regimen.

To study the effects of treatment approach on parameters of HIV disease, measurements of cluster of differentiation 4 (CD4) cells and viral loads will be made at baseline and at the completion of therapy, and then 2 months following the end of treatment, and then every 3-6 months for a total of 24 months following chemotherapy.

03

Conditions studied

  • Lymphoma, AIDS-related
  • Lymphoma, Large B-Cell, Diffuse

Keywords

  • AIDS
  • Malignancy
  • Antiretroviral
  • Chemotherapy
  • Monoclonal
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Aggressive B-lymphocyte antigen CD20 (CD20) positive Diffuse Large B-cell lymphoma confirmed by Laboratory of Pathology, National Cancer Institute (NCI). Note: Participants with aggressive B-cell lymphoma of the plasmablastic lymphoma sub-type who do not have surface CD20 expression, are also eligible.

(HIV) + serology.

All stages (I-IV) of disease.

(ECOG) Performance status 0-4

Non-Hodgkin's Lymphoma (NHL) previously untreated with cytotoxic chemotherapy; however, participants may be entered if they have had prior cyclophosphamide for an urgent problem at diagnosis (e.g., epidural cord compression, superior vena cava syndrome) and/or a single dose of intrathecal methotrexate (MTX) at the time of the pre-treatment diagnostic lumbar puncture

Age greater than or equal to 18 years

Laboratory tests (unless impairment due to respective organ involvement by tumor):

  • Creatinine less than or equal to 1.5 mg/dl or greater than or equal to 50 ml/min
  • less than 2.0 mg/dl, or total bilirubin less than or equal to 4.5 mg/dl with direct fraction less than or equal to 0.3 mg/dl in participants for whom these abnormalities are felt to be due to protease inhibitor therapy
  • (AST) and alanine aminotransferase (ALT) less than or equal to 3x (ULN) (AST and ALT less than or equal to 6x ULN for participants on hyperalimentation for whom these abnormalities are felt to be due to the hyperalimentation)
  • (ANC) greater than or equal to 1000/mm(3)
  • greater than or equal to 75,000/mm(3) (unless impairment due to Immune thrombocytopenic purpura (ITP)

Ability of participant to provide .

Exclusion criteria

EXCLUSION CRITERIA:

Previous rituximab

Pregnancy or nursing.

- Doxorubicin, etoposide, vincristine and cyclophosphamide are teratogenic and may be excreted in milk.

Current clinical heart failure or symptomatic ischemic heart disease.

Serious underlying medical condition or infection other than that would contraindicate subcutaneous (SC)-rituximab, etoposide phosphate, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride (hydroxydaunorubicin (EPOCH-R).

  • Examples include, but are not limited to:
  • Severe Acquired immunodeficiency syndrome (AIDS)-related wasting
  • Sever intractable diarrhea
  • Active inadequately treated opportunistic infection of the central nervous system (CNS)
  • Primary CNS lymphoma

Primary CNS lymphoma

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
68 participants (actual)

Study arms

  • Experimental
    Arm 1-Combination Chemo and Biological Therapy

    Combination chemo and biological therapy

    Biological: Rituximab · Biological: Filgrastim · Drug: EPOCH

Interventions

  • BiologicalRituximab

    2 doses of rituximab every cycle: first dose on Day 1 and 2nd dose on Day 5

    Also known as: Rituxan

  • BiologicalFilgrastim

    Filgrastim day 6 until absolute neutrophil count (ANC) reaches 5000 after the nadir, every cycle

    Also known as: Neupogen

  • DrugEPOCH

    Drug page: Epoetin AlfaStudies of Epoetin AlfaEpoetin Alfa pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    combination chemotheray: EPOCH every 3 weeks for minimum of 3 cycles and max of 6 cycles

    Also known as: etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin hydrochloride

06

What researchers measure

Primary outcomes

  1. Median Progression Free Survival (PFS)

    PFS is the time interval from study entry to documented evidence of disease progression or death due to any cause. Progression is defined according to the Cheson response criteria. Disease progression is defined as increase of 25% or more in the sum of the products of the longest perpendicular diameters of all measured lesions compared to the smallest previous measurements, or the appearance of any new lesion(s). Confidence intervals were made, and a Kaplan-Meier curve of progression free survival was constructed.

    Time frame: The participants were followed for a median of 15.4 years.

  2. Progression Free Survival at 1 Year

    PFS is the time interval from start of treatment to documented evidence of disease progression. Progression is defined according to the Cheson response criteria. Disease progression as indicated by imaging scans at one year following therapy. Disease progression is defined as increase of 25% or more in the sum of the products of the longest perpendicular diameters of all measured lesions compared to the smallest previous measurements, or the appearance of any new lesion(s).

    Time frame: 1 year

Secondary outcomes

  1. Number of Participants With ≥ Grades 3-5 Non-hematologic Toxicity

    Non-hematologic (i.e., not begin in bone marrow or blood) toxicity was assessed by the Common Toxicity Criteria (CTC v2.0). Grade 3 is severe. Grade 4 is life-threatening. Grade 5 is death related to adverse event.

    Time frame: Date treatment consent signed to date off study, approximately 209 months and 17 days.

  2. Median Overall Survival

    Overall survival is time from treatment start date until date of death or date last known alive.

    Time frame: The participants were followed for survival for a median of 15.4 years.

  3. 1 Year Overall Survival

    Overall survival is time from treatment start date until date of death or date last known alive.

    Time frame: 1 year

  4. Median Duration of Complete Response/Complete Response Unconfirmed

    Complete response (CR) was assessed by the Cheson response criteria. Complete response is disappearance of all signs and symptoms of lymphoma for a period of at least one month. All lymph nodes and nodal masses must have regressed to normal size (1.5 cm in their greatest transverse diameter for nodes \> 1.5 cm before therapy). Complete response unconfirmed (CRu) is when a residual lymph node mass \> 1.5 cm in greatest transverse diameter that has regressed by \> 75% in sum of the products of the greatest diameters, does not change over the last two treatments, and any biopsies obtained are negative will be considered to be in CR. In organs involved by disease, any residual lesions that have decreased by \> 75% in sum of the products of the greatest diameters or are \< 1 cm, are consistent with scar, and stable over the last two treatments will be considered to fulfill criteria for CR.

    Time frame: The participants were followed for duration of complete response or complete response unconfirmed for a median of 15.4 years.

  5. Percentage of Participants With CR/CRu Lasting 1 Year

    Complete response (CR) was assessed by the Cheson response criteria. Complete response is disappearance of all signs and symptoms of lymphoma for a period of at least one month. All lymph nodes and nodal masses must have regressed to normal size (1.5 cm in their greatest transverse diameter for nodes \> 1.5 cm before therapy). Complete response unconfirmed (CRu) is when a residual lymph node mass \> 1.5 cm in greatest transverse diameter that has regressed by \> 75% in sum of the products of the greatest diameters, does not change over the last two treatments, and any biopsies obtained are negative will be considered to be in CR. In organs involved by disease, any residual lesions that have decreased by \> 75% in sum of the products of the greatest diameters or are \< 1 cm, are consistent with scar, and stable over the last two treatments will be considered to fulfill criteria for CR.

    Time frame: 1 year

  6. Number of Participants With at Least One Hematologic Toxicity Event of Febrile Neutropenia

    Toxicity was assessed by the Common Toxicity Criteria (CTC v2.0). Febrile neutropenia is defined as a life-threatening complication requiring hospitalization and urgent broad-spectrum antibiotics.

    Time frame: Date treatment consent signed to date off study, approximately 209 months and 17 days.

  7. Number of Cycles of Hematologic Toxicity

    Cumulative number of cycles of hematologic toxicity. Hematologic (i.e., decrease in bone marrow and blood cells) toxicity was assessed by the Common Toxicity Criteria (CTC v2.0).

    Time frame: Up to 112 cycles (each cycle is 21 days + 7 days window)

  8. Overall Response

    Overall response was determined by the Cheson Response Criteria. Participants with either a complete response (CR), complete response unconfirmed or partial response were considered responders. Less than a partial response was considered a non-response to therapy (i.e., Stable Disease and/or Progressive Disease). Complete response was defined as the disappearance of all signs and symptoms of lymphoma for a period of at least one month. All lymph nodes and nodal masses must have regressed to normal size. Complete response unconfirmed is a residual lymph node mass \> 1.5 cm in greatest transverse diameter that has regressed by \> 75% in sum of the products of the greatest diameters, does not change over the last two treatments, and any biopsies obtained are negative will be considered to be in CR. Partial response is defined as a 50% or greater decrease in the sum of the products of the longest perpendicular diameters of all measured lesions lasting for a period of at least one month.

    Time frame: The participants were followed for an average of 6 months to determine response to therapy.

  9. Percentage of Participants With Complete Response

    Complete response was assessed by the Cheson Response Criteria. Complete response is disappearance of all signs and symptoms of lymphoma for a period of at least one month. All lymph nodes and nodal masses must have regressed to normal size (1.5 cm in their greatest transverse diameter for nodes \> 1.5 cm before therapy).

    Time frame: The participants were followed for an average of 6 months to determine response to therapy.

  10. Median Interim Positron Emission Tomography (PET) Positive Progression Free Survival (PFS)

    PFS is the time interval from start of treatment to documented evidence of disease progression or death from any cause. Disease progression was assessed by positron emission tomography scans after 2 cycles (each cycle is 21 days + 7 days window) of therapy using the Deauville criteria. Deauville score of 4 or 5 is considered positive on interim PET scan while a Deauville score of 1 or 2 or 3 is considered negative. The outcomes of the Deauville score was compared to determine PET positive progression free survival.

    Time frame: Participants were followed for up to 10.2 years to determine their response on interim PET scans.

  11. 1 Year Interim Positron Emission Tomography (PET) Positive Progression Free Survival (PFS)

    1-year PFS is defined as participants who remain free of disease progression or death at one year from study entry. We compared the 1-year PFS of participants with negative results on interim positron emission tomography (PET) scans to those with positive results on interim PET scans. PFS is defined as the time interval from start of treatment to documented evidence of disease progression or death from any cause. Disease progression was assessed by positron emission tomography scans after 2 cycles of therapy using the Deauville criteria. Deauville score of 4 or 5 is considered positive on interim PET scan while a Deauville score of 1 or 2 or 3 is considered negative. The outcomes of the Deauville score was compared to determine PET positive progression free survival.

    Time frame: 1 year

  12. Recovery of CD4 T Cells (CD4) Counts

    Participants with human immunodeficiency virus (HIV) who undergo chemotherapy may have a delay in the recovery of their normal CD4+ T-cells. This delay could result in an increased risk of infection. Recovery of CD4 cells counts is the time from end of therapy until the time that the CD4 counts first reached above 200 cells/uL.

    Time frame: From the end of chemotherapy every 3 months for the first 2 years

  13. Recovery of Human Immunodeficiency Virus (HIV) Viral Load

    The HIV viral load is a measure of actively replicating virus in the blood. If no anti-retroviral therapy is given, then reduction of this HIV viral load to manageable levels might risk infection. In our study, the recovery of HIV viral load was measured the time from the initiation of antiretroviral therapy until the viral load was undetectable or \< 50 copies.

    Time frame: Either following or concurrently with combination chemo and biological therapy, approximately every 6 to 8 weeks after therapy was completed up to 16 months

Other outcomes

  1. Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Toxicity Criteria (CTC v2.0)

    Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Toxicity Criteria (CTC v2.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.

    Time frame: Date treatment consent signed to date off study, approximately 209 months and 17 days.

07

Results

Posted Jun 28, 2022

Participant flow

Participant flow — Overall Study
MilestoneArm 1-Combination Chemo and Biological Therapy
Started68
Completed65
Not completed3
Withdrew: Refused further treatment2
Withdrew: Declined to participate (before treatment started)1

Outcome measures

PrimaryMedian Progression Free Survival (PFS)

PFS is the time interval from study entry to documented evidence of disease progression or death due to any cause. Progression is defined according to the Cheson response criteria. Disease progression is defined as increase of 25% or more in the sum of the products of the longest perpendicular diameters of all measured lesions compared to the smallest previous measurements, or the appearance of any new lesion(s). Confidence intervals were made, and a Kaplan-Meier curve of progression free survival was constructed.

Time frame:
The participants were followed for a median of 15.4 years.
Reported as:
Median · years
Median Progression Free Survival (PFS)
yearsArm 1-Combination Chemo and Biological Therapy
Median Progression Free Survival (PFS)13.8 (10.2 to NA)
PrimaryProgression Free Survival at 1 Year

PFS is the time interval from start of treatment to documented evidence of disease progression. Progression is defined according to the Cheson response criteria. Disease progression as indicated by imaging scans at one year following therapy. Disease progression is defined as increase of 25% or more in the sum of the products of the longest perpendicular diameters of all measured lesions compared to the smallest previous measurements, or the appearance of any new lesion(s).

Time frame:
1 year
Reported as:
Number · percentage of participants
Progression Free Survival at 1 Year
percentage of participantsArm 1-Combination Chemo and Biological Therapy
Progression Free Survival at 1 Year79.1 (67.3 to 87.1)
SecondaryNumber of Participants With ≥ Grades 3-5 Non-hematologic Toxicity

Non-hematologic (i.e., not begin in bone marrow or blood) toxicity was assessed by the Common Toxicity Criteria (CTC v2.0). Grade 3 is severe. Grade 4 is life-threatening. Grade 5 is death related to adverse event.

Time frame:
Date treatment consent signed to date off study, approximately 209 months and 17 days.
Reported as:
Count of participants · Participants
Number of Participants With ≥ Grades 3-5 Non-hematologic Toxicity
ParticipantsGrade 3Grade 4Grade 5
Serious infection1700
Neurologic event000
Syncope100
Confusion100
Motor neuropathy010
Vision disturbance100
Hyperglycemia400
Hypophosphatemia210
Hypocalcemia200
Hypokalemia110
Hyponatremia100
Dehydration100
Mucositis/Stomatitis600
Liver test abnormalities610
Pancreatitis100
Diarrhea200
Constipation100
Serious hemorrhage510
Fatigue200
Headache500
Bone pain100
Nausea010
Anorexia010
Hypoxia041
Myelodysplastic syndrome001
SecondaryMedian Overall Survival

Overall survival is time from treatment start date until date of death or date last known alive.

Time frame:
The participants were followed for survival for a median of 15.4 years.
Reported as:
Median · years
Median Overall Survival
yearsArm 1-Combination Chemo and Biological Therapy
Median Overall Survival14.2 (13.2 to NA)
Secondary1 Year Overall Survival

Overall survival is time from treatment start date until date of death or date last known alive.

Time frame:
1 year
Reported as:
Number · percentage of participants
1 Year Overall Survival
percentage of participantsArm 1-Combination Chemo and Biological Therapy
1 Year Overall Survival83.7 (71.0 to 91.2)
SecondaryMedian Duration of Complete Response/Complete Response Unconfirmed

Complete response (CR) was assessed by the Cheson response criteria. Complete response is disappearance of all signs and symptoms of lymphoma for a period of at least one month. All lymph nodes and nodal masses must have regressed to normal size (1.5 cm in their greatest transverse diameter for nodes \> 1.5 cm before therapy). Complete response unconfirmed (CRu) is when a residual lymph node mass \> 1.5 cm in greatest transverse diameter that has regressed by \> 75% in sum of the products of the greatest diameters, does not change over the last two treatments, and any biopsies obtained are negative will be considered to be in CR. In organs involved by disease, any residual lesions that have decreased by \> 75% in sum of the products of the greatest diameters or are \< 1 cm, are consistent with scar, and stable over the last two treatments will be considered to fulfill criteria for CR.

Time frame:
The participants were followed for duration of complete response or complete response unconfirmed for a median of 15.4 years.
Reported as:
Median · years
Median Duration of Complete Response/Complete Response Unconfirmed
yearsArm 1-Combination Chemo and Biological Therapy
Median Duration of Complete Response/Complete Response Unconfirmed13.9 (13.1 to NA)
SecondaryPercentage of Participants With CR/CRu Lasting 1 Year

Complete response (CR) was assessed by the Cheson response criteria. Complete response is disappearance of all signs and symptoms of lymphoma for a period of at least one month. All lymph nodes and nodal masses must have regressed to normal size (1.5 cm in their greatest transverse diameter for nodes \> 1.5 cm before therapy). Complete response unconfirmed (CRu) is when a residual lymph node mass \> 1.5 cm in greatest transverse diameter that has regressed by \> 75% in sum of the products of the greatest diameters, does not change over the last two treatments, and any biopsies obtained are negative will be considered to be in CR. In organs involved by disease, any residual lesions that have decreased by \> 75% in sum of the products of the greatest diameters or are \< 1 cm, are consistent with scar, and stable over the last two treatments will be considered to fulfill criteria for CR.

Time frame:
1 year
Reported as:
Number · percentage of participants
Percentage of Participants With CR/CRu Lasting 1 Year
percentage of participantsArm 1-Combination Chemo and Biological Therapy
Percentage of Participants With CR/CRu Lasting 1 Year82.5 (70.7 to 89.9)
SecondaryNumber of Participants With at Least One Hematologic Toxicity Event of Febrile Neutropenia

Toxicity was assessed by the Common Toxicity Criteria (CTC v2.0). Febrile neutropenia is defined as a life-threatening complication requiring hospitalization and urgent broad-spectrum antibiotics.

Time frame:
Date treatment consent signed to date off study, approximately 209 months and 17 days.
Reported as:
Count of participants · Participants
Number of Participants With at Least One Hematologic Toxicity Event of Febrile Neutropenia
ParticipantsArm 1-Combination Chemo and Biological Therapy
Number of Participants With at Least One Hematologic Toxicity Event of Febrile Neutropenia18
SecondaryNumber of Cycles of Hematologic Toxicity

Cumulative number of cycles of hematologic toxicity. Hematologic (i.e., decrease in bone marrow and blood cells) toxicity was assessed by the Common Toxicity Criteria (CTC v2.0).

Time frame:
Up to 112 cycles (each cycle is 21 days + 7 days window)
Reported as:
Number · cycles
Number of Cycles of Hematologic Toxicity
cyclesArm 1-Combination Chemo and Biological Therapy
Febrile neutropenia25
Neutropenia with a Nadir <500 cells/mm^3112
Neutropenia with a Nadir <100 cells/mm^377
Thrombocytopenia with a Nadir <50,000 platelets/mm^340
Thrombocytopenia with a Nadir <25,000 platelets/mm^36
Anemia: hemoglobin <8 g/dL36
SecondaryOverall Response

Overall response was determined by the Cheson Response Criteria. Participants with either a complete response (CR), complete response unconfirmed or partial response were considered responders. Less than a partial response was considered a non-response to therapy (i.e., Stable Disease and/or Progressive Disease). Complete response was defined as the disappearance of all signs and symptoms of lymphoma for a period of at least one month. All lymph nodes and nodal masses must have regressed to normal size. Complete response unconfirmed is a residual lymph node mass \> 1.5 cm in greatest transverse diameter that has regressed by \> 75% in sum of the products of the greatest diameters, does not change over the last two treatments, and any biopsies obtained are negative will be considered to be in CR. Partial response is defined as a 50% or greater decrease in the sum of the products of the longest perpendicular diameters of all measured lesions lasting for a period of at least one month.

Time frame:
The participants were followed for an average of 6 months to determine response to therapy.
Reported as:
Count of participants · Participants
Overall Response
ParticipantsArm 1-Combination Chemo and Biological Therapy
Complete Response53
Complete Response Unconfirmed10
Partial Response1
Non-Responder - Stable Disease1
Non-Responder - Progressive Disease1
SecondaryPercentage of Participants With Complete Response

Complete response was assessed by the Cheson Response Criteria. Complete response is disappearance of all signs and symptoms of lymphoma for a period of at least one month. All lymph nodes and nodal masses must have regressed to normal size (1.5 cm in their greatest transverse diameter for nodes \> 1.5 cm before therapy).

Time frame:
The participants were followed for an average of 6 months to determine response to therapy.
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Response
percentage of participantsArm 1-Combination Chemo and Biological Therapy
Percentage of Participants With Complete Response95
SecondaryMedian Interim Positron Emission Tomography (PET) Positive Progression Free Survival (PFS)

PFS is the time interval from start of treatment to documented evidence of disease progression or death from any cause. Disease progression was assessed by positron emission tomography scans after 2 cycles (each cycle is 21 days + 7 days window) of therapy using the Deauville criteria. Deauville score of 4 or 5 is considered positive on interim PET scan while a Deauville score of 1 or 2 or 3 is considered negative. The outcomes of the Deauville score was compared to determine PET positive progression free survival.

Time frame:
Participants were followed for up to 10.2 years to determine their response on interim PET scans.
Reported as:
Median · years
Median Interim Positron Emission Tomography (PET) Positive Progression Free Survival (PFS)
yearsArm 1-Combination Chemo and Biological Therapy
Interim PET positive participants10.2 (0.4 to NA)
Interim PET negative participantsNA (NA to NA)
Statistical analysis
  • Arm 1-Combination Chemo and Biological Therapy · Two-tailed log rank test · p = 0.10
Secondary1 Year Interim Positron Emission Tomography (PET) Positive Progression Free Survival (PFS)

1-year PFS is defined as participants who remain free of disease progression or death at one year from study entry. We compared the 1-year PFS of participants with negative results on interim positron emission tomography (PET) scans to those with positive results on interim PET scans. PFS is defined as the time interval from start of treatment to documented evidence of disease progression or death from any cause. Disease progression was assessed by positron emission tomography scans after 2 cycles of therapy using the Deauville criteria. Deauville score of 4 or 5 is considered positive on interim PET scan while a Deauville score of 1 or 2 or 3 is considered negative. The outcomes of the Deauville score was compared to determine PET positive progression free survival.

Time frame:
1 year
Reported as:
Number · percentage of participants
1 Year Interim Positron Emission Tomography (PET) Positive Progression Free Survival (PFS)
percentage of participantsArm 1-Combination Chemo and Biological Therapy
Interim PET scan positive 1-year PFS61.5 (30.8 to 81.8)
Interim PET scan negative 1 year PFS89.3 (70.4 to 96.3)
SecondaryRecovery of CD4 T Cells (CD4) Counts

Participants with human immunodeficiency virus (HIV) who undergo chemotherapy may have a delay in the recovery of their normal CD4+ T-cells. This delay could result in an increased risk of infection. Recovery of CD4 cells counts is the time from end of therapy until the time that the CD4 counts first reached above 200 cells/uL.

Time frame:
From the end of chemotherapy every 3 months for the first 2 years
Reported as:
Median · months
Recovery of CD4 T Cells (CD4) Counts
monthsArm 1-Combination Chemo and Biological Therapy
Recovery of CD4 T Cells (CD4) Counts2.5 (0 to 24)
SecondaryRecovery of Human Immunodeficiency Virus (HIV) Viral Load

The HIV viral load is a measure of actively replicating virus in the blood. If no anti-retroviral therapy is given, then reduction of this HIV viral load to manageable levels might risk infection. In our study, the recovery of HIV viral load was measured the time from the initiation of antiretroviral therapy until the viral load was undetectable or \< 50 copies.

Time frame:
Either following or concurrently with combination chemo and biological therapy, approximately every 6 to 8 weeks after therapy was completed up to 16 months
Reported as:
Median · months
Recovery of Human Immunodeficiency Virus (HIV) Viral Load
monthsArm 1-Combination Chemo and Biological Therapy
Recovery of Human Immunodeficiency Virus (HIV) Viral Load2 (0 to 16)
Other pre-specifiedNumber of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Toxicity Criteria (CTC v2.0)

Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Toxicity Criteria (CTC v2.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.

Time frame:
Date treatment consent signed to date off study, approximately 209 months and 17 days.
Reported as:
Count of participants · Participants
Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Toxicity Criteria (CTC v2.0)
ParticipantsArm 1-Combination Chemo and Biological Therapy
Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Toxicity Criteria (CTC v2.0)66

Adverse events

Collected over Date treatment consent signed to date off study, approximately 209 months and 17 days.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm 1-Combination Chemo and Biological Therapy12/67 (17.9%)23/67 (34.3%)66/67 (98.5%)
Most frequent serious events
Showing 10 of 32
Most frequent serious events
EventArm 1-Combination Chemo and Biological Therapy
Febrile neutropeniaInfections and infestations6/67
HeadacheNervous system disorders4/67
CNS hemorrhage/bleedingNervous system disorders3/67
Fever (in the absence of neutropenia, where neutropenia is defined as AGC<1.0 x 10e9/L)Infections and infestations3/67
Infection without neutropeniaInfections and infestations3/67
ConstipationGastrointestinal disorders2/67
NauseaGastrointestinal disorders2/67
PlateletsBlood and lymphatic system disorders2/67
Secondary Malignancy-Other (Myelodysplasia/Leukemia) excludes metastasis from initial primaryNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/67
Vision-blurred visionEye disorders2/67
Most frequent other events
Showing 10 of 145
Most frequent other events
EventArm 1-Combination Chemo and Biological Therapy
Neutrophils/granulocytes (ANC/AGC)Blood and lymphatic system disorders62/67
Leukocytes (total WBC)Blood and lymphatic system disorders61/67
HemoglobinBlood and lymphatic system disorders60/67
LymphopeniaBlood and lymphatic system disorders58/67
PlateletsBlood and lymphatic system disorders56/67
Stomatitis/pharyngitis (oral/pharyngeal mucositis)Gastrointestinal disorders36/67
NauseaGastrointestinal disorders33/67
SGPT (ALT) (serum glutamic pyruvic transaminase)Hepatobiliary disorders33/67
Fatigue (lethargy, malaise, asthenia)General disorders32/67
Neuropathy-sensoryNervous system disorders31/67

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Arm 1-Combination Chemo and Biological Therapy
<=18 years2
Between 18 and 65 years66
>=65 years0
Age, Continuous
Age, Continuous(years)Arm 1-Combination Chemo and Biological Therapy
Mean42.36 ± 10.7
Sex: Female, Male
Sex: Female, Male(Participants)Arm 1-Combination Chemo and Biological Therapy
Female11
Male57
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm 1-Combination Chemo and Biological Therapy
Hispanic or Latino6
Not Hispanic or Latino62
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm 1-Combination Chemo and Biological Therapy
American Indian or Alaska Native0
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American32
White31
More than one race0
Unknown or Not Reported3
Region of Enrollment
Region of Enrollment(Participants)Arm 1-Combination Chemo and Biological Therapy
United States68
08

Study locations

1 site
  • National Institutes of Health Clinical Center, 9000 Rockville Pike
    Bethesda, Maryland 20892, United States
09

References and documents

Publications

  • Kurtz DM, Scherer F, Jin MC, Soo J, Craig AFM, Esfahani MS, Chabon JJ, Stehr H, Liu CL, Tibshirani R, Maeda LS, Gupta NK, Khodadoust MS, Advani RH, Levy R, Newman AM, Duhrsen U, Huttmann A, Meignan M, Casasnovas RO, Westin JR, Roschewski M, Wilson WH, Gaidano G, Rossi D, Diehn M, Alizadeh AA. Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2018 Oct 1;36(28):2845-2853. doi: 10.1200/JCO.2018.78.5246. Epub 2018 Aug 20. PubMed 30125215 ↗
  • Dunleavy K, Pittaluga S, Shovlin M, Steinberg SM, Cole D, Grant C, Widemann B, Staudt LM, Jaffe ES, Little RF, Wilson WH. Low-intensity therapy in adults with Burkitt's lymphoma. N Engl J Med. 2013 Nov 14;369(20):1915-25. doi: 10.1056/NEJMoa1308392. PubMed 24224624 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — All individual participant data (IPD) recorded in the medical record will be shared with intramural investigators upon request. All large-scale genomic sequencing data will be shared with subscribers to database of Genotypes and Phenotypes (dbGaP).

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Clinical data available during the study and indefinitely. Genomic data are available once genomic data are uploaded per protocol genomic data sharing (GDS) plan for as long as database is active.

Access criteria: Clinical data will be made available via subscription to Biomedical Translational Research Information System (BTRIS) and with the permission of the study principal investigator (PI). Genomic data are made available via database of Genotypes and Phenotypes (dbGaP) through requests to the data custodians.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2001 to primary completion in Nov 2020, 238 months.

Results were first posted in Jun 2022, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2000
First posted
Nov 6, 2000
StartActual
Jan 29, 2001
Primary completionActual
Nov 30, 2020
CompletionActual
Jan 18, 2024
Results first posted
Jun 28, 2022
Last update
Aug 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00006436
Responsible party
Christopher Melani, MD (Principal Investigator, National Cancer Institute (NCI)) — Principal investigator
First posted
Nov 6, 2000
Start date
Jan 29, 2001
Primary completion
Nov 30, 2020
Completion
Jan 18, 2024
Results posted
Jun 28, 2022
Last update
Aug 3, 2026

Study contacts

Christopher Melani, M.D.
principal investigator · National Cancer Institute (NCI)

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rituximab · Epoetin Alfa

Start the discussion